Stock Evaluator: Bionano Genomics, Inc. (BNGO)

Bionano Genomics, Inc. BNGO

$1.07 0.01 0.94%
July 31, 2026 4:00:00 PM EST November 10, 2021 Volume: 237,382
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Life Sciences Tools & Services

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Commentary & Analysis


Financial Summary

Share Statistics BNGO Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $12.3 $1,790.4 8%
Shares Out (Mil) 11.0 94.8 22%
Institutional Ownership 99.8% 90.0% 94%
Float (Mil) 10.3 69.9 20%
Beta 1.63 1.20 85%
Avg Daily Volume (000s) 107 814 36%
Price Change
(52-week)
(64.6%) 80.2% 11%
Growth BNGO Industry
Median
Percentile
(All Stocks)
Sales (5yr) 27.4% 7.8% 88%
Net Income (5yr) 8.5% (13.7%) 52%
EPS (5yr) 54.0% 0.7% 94
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (15.0%) (15.0%) 52%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na 1 1
Current EPS ($0.670) ($2.710) ($1.110)
Month Ago EPS na ($2.710) ($1.110)
# Rev Up 1 0 0
# Rev Down 0 1 1
Three Months Ago EPS ($0.890) ($2.710) ($1.110)
Year/Year Chg (11.4%) (44.1%) (89.3%)
Financials BNGO Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $29 $785 15%
Net Income (TTM) (Mil) ($32) ($14) 20%
EPS (TTM) ($4.204) ($0.200) 9%
Operating Cash Flow (TTM) (Mil) ($19) $53 15%
Net Cash Flow (TTM) (Mil) $1 ($4) 48%
Long-Term Debt (Q1) (Mil) $6 $270 26%
Enterprise Value (Q1) (Mil) $16 $2,444 10%
Valuation BNGO Industry
Median
Percentile
(All Stocks)
P/B 0.32 2.92 5%
P/E na 43.7 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 5.3 na
Ratios BNGO Industry
Median
Percentile
(All Stocks)
Gross Margin 47.0% 47.6% 59%
Net Margin (109.9%) (2.9%) 7%
ROA (44.1%) (2.8%) 13%
ROE (73.8%) (4.5%) 12%
Liabilities to Assets 42.2% 43.0% 33%
F-Score 5 5 51%

Bionano Genomics, Inc. did not pass any screens on 7/31/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors